Richardson, P. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S., Lonial, S., Laubach, J., . . . Anderson, K. C. (2017). Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia.
Dyfyniad Arddull ChicagoRichardson, P G., et al. "Pomalidomide, Bortezomib and Low-dose Dexamethasone in Lenalidomide-refractory and Proteasome Inhibitor-exposed Myeloma." Leukemia 2017.
Dyfyniad MLARichardson, P G., et al. "Pomalidomide, Bortezomib and Low-dose Dexamethasone in Lenalidomide-refractory and Proteasome Inhibitor-exposed Myeloma." Leukemia 2017.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.